Introduction
============

Adipose tissue has been characterized as an endocrine organ which secretes proinflammatory adipocytokines, including leptin, tumor necrosis factor-alpha, and interleukin-1β.[@b1-ceg-7-199] Visceral fat plays a key role in obesity-related metabolic dysfunction. Obesity, in turn, is associated with multiple comorbidities, including diabetes, hypertension, and hyperlipidemia. Obesity is also associated with fatty infiltration of organs including the heart, kidneys, and liver. Under conditions of oxidative stress, fat-derived cytokines are released locally and result in an inflammatory process and organ dysfunction.[@b2-ceg-7-199]

Increased infiltration of fat in the pancreas has been seen with obesity, senescence, Cushing's syndrome, cystic fibrosis, and lipomatous pseudohypertrophy.[@b2-ceg-7-199] Extreme fatty replacement of the exocrine pancreas may be associated with a decrease in pancreatic function.[@b2-ceg-7-199] Patients who are obese have been documented to have more severe pancreatitis than lean individuals. It has been postulated that a fatty pancreas may be more prone to pancreatitis, similar to the development of nonalcoholic steatohepatitis as a result of nonalcoholic fatty liver disease.[@b3-ceg-7-199]

Pancreatitis complicates 1%--22% of endoscopic retrograde cholangiopancreatography (ERCP) procedures.[@b4-ceg-7-199] Obesity is not a clear patient risk factor for post-ERCP pancreatitis. An association between fatty pancreas and postoperative pancreatic fistulae has been reported.[@b5-ceg-7-199] Higher fat content has been observed in the pancreas of patients presenting with pancreatitis secondary to sphincter of Oddi dysfunction compared with patients with sphincter of Oddi dysfunction without pancreatitis.[@b6-ceg-7-199]

Magnetic resonance imaging (MRI) can accurately assess tissue fat content by utilizing the slight differences in the MRI signal of hydrogen nuclei in fat and water molecules. Chemical shift imaging has been shown to be accurate in assessment of hepatic fat content compared with liver biopsy[@b7-ceg-7-199]--[@b9-ceg-7-199] and in the assessment of fat in adrenal tumors to distinguish between benign and malignant lesions.[@b10-ceg-7-199]--[@b12-ceg-7-199] Typical MRI images in cases with post-ERCP pancreatitis and controls are shown in [Figures 1](#f1-ceg-7-199){ref-type="fig"} and [2](#f2-ceg-7-199){ref-type="fig"}, respectively. This study sought a correlation between pancreatic fat content as assessed by MRI and occurrence of pancreatitis post-ERCP. Fat content is a parameter that can be identified before ERCP. If the study showed increased post-ERCP pancreatitis with increased fat content, it would help with risk stratification and patient consent, and potentially alter management during the procedure, ie, use of pancreatic duct stents or nonsteroidal anti-inflammatory drugs.

Materials and methods
=====================

Patients
--------

We conducted a case control study of patients who underwent MRI/magnetic resonance cholangiopancreatography (MRCP) and ERCP at the Indiana University Medical Center. Subjects included patients who had an abdominal MRI/MRCP followed by an ERCP no more than 60 days later from September 2003 to January 2011. Permission to review a database maintained to monitor the care of these patients was granted by the institutional review board at Clarian Health Partners/Indiana University, Purdue University, Indianapolis, IN, USA. Case subjects were patients who developed post-ERCP pancreatitis. Control subjects included patients who underwent ERCP without developing pancreatitis who were matched for age, gender, and indications for ERCP. Standard definitions of post-ERCP pancreatitis and severity were used.[@b13-ceg-7-199] All ERCPs were done by six faculty members and eight advance endoscopy fellows in training. No one person did more than ten cases.

MRI analysis
------------

All MRI images were reviewed, with emphasis on fat content of the head, body, and tail of the pancreas, by an abdominal radiologist (SK) with 13 years of experience in interpreting abdominal MRI. The percentage fat was determined by recording the signal intensity in the in-phase (S~in~) and out-of-phase (S~out~) T1-weighted gradient echo sequences and subsequently calculating the fat fraction as (S~in~ − S~out~)/(S~in~ × 2).

Inclusion and exclusion criteria
--------------------------------

All patients who had an MRCP followed by ERCP within 60 days for suspected sphincter of Oddi dysfunction, pancreas divisum, or evaluation of acute recurrent pancreatitis were selected. Patients with pancreatic cancer, pseudocysts, chronic pancreatitis (diagnosed before ERCP such as by computed tomography scan) or biliary tract disease were excluded. Patients who had intervening pancreatic surgery between MRI and ERCP were also excluded.

Statistical analysis
--------------------

The statistical analysis was performed using the Statistical Package for Social Sciences version 17.0 (SPSS Inc, Chicago, IL, USA).The chi-square test was used to assess for differences in baseline characteristics between the two groups. If the expected count of each cell was less than five, Fisher's exact test was used to evaluate the difference between groups. The Student's *t*-test was used to compare the mean pancreatic fat content between the groups. Stepwise logistic regression analysis was performed to find the best predictor(s) of post-ERCP pancreatitis. At each step, the likelihood ratio test was used to determine if the parameter was to be entered into the model. The fat content of the head, body, and tail of the pancreas, as well as age, gender, and body mass index were evaluated as parameters. Correlation analysis was used to investigate the relationship between body mass index and pancreatic fat content. A *P* value \< 0.05 was considered to be statistically significant.

Results
=======

We identified 47 patients who developed post-ERCP pancreatitis and had an MRI within 60 days of their ERCP. A further 74 subjects underwent MRI followed by ERCP within 60 days and did not develop post-ERCP pancreatitis. Cases of post-ERCP pancreatitis and controls did not differ with respect to age (41.4 years versus 41.1 years, *P* = 0.89) or gender (21.2% versus 20.2% males, *P* = 0.8). [Table 1](#t1-ceg-7-199){ref-type="table"} summarizes the patient characteristics and demographics. There were no statistically significant differences between the two groups for baseline parameters, as shown in [Table 1](#t1-ceg-7-199){ref-type="table"}. Both groups were similar with respect to indications for ERCP, extent of pancreatic duct filling, manometry measurements, pancreatic duct stent placement, history of post-ERCP pancreatitis, history of recurrent acute pancreatitis, and evidence of chronic pancreatitis ([Table 2](#t2-ceg-7-199){ref-type="table"}), except that the pancreatitis group underwent more biliary and pancreatic sphincterotomies.

[Table 3](#t3-ceg-7-199){ref-type="table"} summarizes the fat content between the two groups. [Figures 3](#f3-ceg-7-199){ref-type="fig"} and [4](#f4-ceg-7-199){ref-type="fig"} show the distribution of fat content in cases of post-ERCP pancreatitis and controls. The mean fat content in the head of the pancreas (4.9% versus 5.5%) was numerically lower in patients with post-ERCP pancreatitis in comparison with the control population. The mean fat content in the body (6.2% versus 5.4%) and tail (5.3% versus 4.9%) of the pancreas was numerically higher in patients with post-ERCP pancreatitis. None of the differences were statistically significant.

Of the 47 patients with post-ERCP pancreatitis, the pancreatitis was mild in severity in 41, moderate in one, and severe in five patients. The mean fat content of the head (5.2%), body (4.8%), and tail (1.1%) in moderate to severe cases was not significantly different from controls nor from patients with mild pancreatitis (head 4.9%, body 6.5%, tail 5.9% respectively, [Table 4](#t4-ceg-7-199){ref-type="table"}). Further, no statistically significant correlation was found between mean body mass index and fat content of the pancreas in our patient population, as shown in [Table 5](#t5-ceg-7-199){ref-type="table"}.

Discussion
==========

Pancreatitis remains the most frequent complication of ERCP. In high-risk patients, such as those with suspected sphincter of Oddi disturbance, post-ERCP pancreatitis rates are as high as 20%. Numerous studies have addressed this topic. The first challenge in clinical practice is to identify patients at risk of developing post-ERCP pancreatitis, in order to establish whether the risk/benefit ratio is favorable and whether noninvasive diagnostic procedures and/or other therapeutic procedures might be adequate or more appropriate.

There are both patient-related and procedure-related risk factors for the development of post-ERCP pancreatitis. In a review by Freeman et al, young age, female gender, suspected sphincter of Oddi dysfunction, history of prior post-ERCP pancreatitis, recurrent pancreatitis, and absence of chronic pancreatitis were identified as independent patient-related risk factors. Biliary orifice balloon dilatation, difficult cannulation, pancreatic sphincterotomy, and number of pancreas duct injections were significant procedure-related risks for pancreatitis. The degrees of pancreatic duct filling at ERCP and trainee involvement are independent risk factors as well. Patients who are obese have been documented to have more severe gallstone-related and alcohol-related pancreatitis than lean individuals.[@b14-ceg-7-199]--[@b16-ceg-7-199]

The two main techniques used to assess fat content are proton (^1^H) magnetic resonance spectroscopy[@b17-ceg-7-199]--[@b19-ceg-7-199] and chemical shift imaging.[@b20-ceg-7-199]--[@b22-ceg-7-199] Both of these techniques utilize slight differences in the MRI signal of hydrogen nuclei in fat and water molecules. In long-chain aliphatic fat molecules, the hydrogen nuclei (protons) are surrounded by a cloud of electrons. In contrast, in water molecules, the hydrogen nuclei are relatively devoid of electron cover, because the electrons are attracted towards the oxygen nucleus. As a result, fat protons experience a slightly lower local magnetic field, and vibrate (precess) at a lower frequency than water protons. This difference in precessional frequency may be used in chemical shift imaging to acquire images where the signals from water and fat protons are additive (in-phase) and where the signals from the two nuclear species are subtractive (out-of-phase). On out-of-phase images, the signal in tissue where there is a substantial fat content is reduced. The fat fraction of a volume of tissue may be calculated by the formula: (S~in~ − S~out~)/(S~in~ × 2), where S~in~ is the signal intensity of the volume of tissue on in-phase images, and S~out~ is the signal on out-of-phase images.

Fatty pancreas has been the focus of attention over the past few years as a risk factor for developing pancreatitis. It has been implicated in the surgical literature as a risk factor for development of postoperative pancreatic fistulae after pancreatoduodenectomy.[@b5-ceg-7-199] A recent article by Zyromski et al compared pancreatic tissue from leptin-deficient obese mice and lean controls.[@b22-ceg-7-199] They noted the obese mice to have a higher fat content in their pancreatic tissue and increased levels of cytokines, suggesting that a fatty pancreas is more prone to pancreatitis. Also, patients with idiopathic pancreatitis and sphincter of Oddi dysfunction are more likely to have a fatty pancreas than controls.[@b6-ceg-7-199]

Our study addressed the issue of pancreatic fat content as evaluated by MRI and any correlation between fat content and post-ERCP pancreatitis. Despite other studies showing a correlation between increased pancreatic fat content and pancreatic disease, such as fistulae, idiopathic pancreatitis, and cystic fibrosis, no statistically significant correlation was found in this study. Our study evaluated patients at high risk for post-ERCP pancreatitis, but studies of lower-risk patients with post-ERCP pancreatitis, such as those with common bile duct stones, would be of interest.

There are several limitations in our study. First, it had a case control design. Although we compared patients with post-ERCP pancreatitis and alleged post-ERCP pancreatitis risk-matched controls, because the etiology of post-ERCP pancreatitis is not fully understood and multifactorial, we could not control all possible factors. Second, the number of patients with post-ERCP pancreatitis enrolled was small and originated from one center. Although there was no obvious trend showing a correlation between post-ERCP pancreatitis and pancreatic fat content in this study, more data from a multicenter study might possibly show different results. Previous studies have demonstrated a correlation between pancreatic fat content and obesity. Our study failed to show such an association. Given that post-ERCP pancreatitis is relatively uncommon, the small study population might also be a factor. Additional ERCP studies which appear warranted include the following:

-   A prospective study addressing the same issues as our retrospective study (given that some prospective studies have higher post-ERCP pancreatitis rates than retrospective studies)

-   A study attempting to correlate pre-ERCP weight loss and post-ERCP pancreatitis frequency, particularly in morbidly obese patients

-   A larger study with greater statistical power to address further the minor trends shown in [Table 3](#t3-ceg-7-199){ref-type="table"}

-   A larger study with greater statistical power to address the frequency of moderate/severe post-ERCP pancreatitis. In summary, our analysis of patients who developed post-ERCP pancreatitis suggests that increased pancreatic fat content does not increase the risk of post-procedure pancreatitis. Further studies are needed, as outlined above.
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![T1-weighted in-phase (**A**) and out-of-phase (**B**) axial images in 44-year old female who did not have post-ERCP pancreatitis.\
**Notes:** The region-of-interest (ROI) over the pancreas (white circle) show no drop off in signal and indicating a 1% fat content of the body of the gland. The ROI over the liver (dark circle) also show only 2% fat content.\
**Abbreviation:** ERCP, endoscopic retrograde cholangiopancreatography.](ceg-7-199Fig1){#f1-ceg-7-199}

![T1-weighted in-phase (**A**) and out-of-phase (**B**) axial images in 52-year old male who subsequently developed post-ERCP pancreatitis.\
**Notes:** The ROIs over the body (white circle) and tail (yellow circles) of pancreas show significant darkening (dark off) of signal on image B, consistent with a pancreatic body and tail fat content of 29% and 33%, respectively. However, the findings of [Figures 1](#f1-ceg-7-199){ref-type="fig"} and [2](#f2-ceg-7-199){ref-type="fig"} were not uniformly seen in patients who had or did not have post-ERCP pancreatitis.\
**Abbreviation:** ERCP, endoscopic retrograde cholangiopancreatography.](ceg-7-199Fig2){#f2-ceg-7-199}

![Fat content of head, body, and tail of pancreas in patients with PEP.\
**Abbreviation:** PEP, post-endoscopic retrograde cholangiopan-creatography pancreatisis.](ceg-7-199Fig3){#f3-ceg-7-199}

![Fat content of head, body, and tail of pancreas in controls.](ceg-7-199Fig4){#f4-ceg-7-199}

###### 

Baseline patient characteristics

  Patient characteristics   Cases (n = 47)   Controls (n = 74)   *P*-values
  ------------------------- ---------------- ------------------- ------------
  Age (mean, SD)            41.4 ± 15.8      41.1 ± 21.4         0.89
  Gender (females, %)       37 (78.7%)       59 (79.7%)          0.81
  Weight in kg (SD)         71.07 ± 20.1     75.6 ± 19.9         0.08
  Mean BMI (SD)             25.38 ± 4.9      27.96 ± 7.7         0.13
  Hypertension              21.20%           21.60%              1
  Diabetes mellitus         8.50%            14.80%              0.56
  Dyslipidemia              14.80%           16.20%              0.79

**Abbreviations:** BMI, body mass index; SD, standard deviation.

###### 

Cases and controls according to their diagnosis, ERCP findings, history of recurrent acute pancreatitis, history of post-ERCP pancreatitis, and evidence of chronic pancreatitis

                                                                               PEP cases (n = 47)   Controls (n = 74)   *P*-values
  ---------------------------------------------------------------------------- -------------------- ------------------- ------------
  Final diagnosis[\*](#tfn2-ceg-7-199){ref-type="table-fn"}                                                             
   Sphincter of Oddi dysfunction[\*\*](#tfn3-ceg-7-199){ref-type="table-fn"}   35 (74.4%)           65 (87.8%)          0.08
   Pancreatic divisum                                                          7 (14.9%)            8 (10.8%)           0.57
   Pancreatic duct stricture                                                   10 (21.3%)           9 (12.2%)           0.2
   Idiopathic pancreatitis                                                     2 (4.3%)             3 (4.1%)            1
   IPMN                                                                        1 (1.4%)             1 (2.1%)            1
  Pancreatic duct filling                                                                                               
   Head, body, and tail                                                        32 (68%)             42 (56.7%)          0.25
   Head and body                                                               11 (23.4%)           23 (31%             0.41
   Head only                                                                   0                    3 (4%)              0.28
   None                                                                        4 (8.5%)             6 (8.1%)            1
  Manometry measurements                                                                                                
   Biliary and pancreatic                                                      26 (55.3%)           37 (50%)            0.58
   Biliary only                                                                5 (10.6%)            14 (18.9%)          0.3
   Pancreatic only                                                             6 (12.8%)            12 (16.2%)          0.79
   None                                                                        10 (21.3%)           11 (14.9%)          0.46
  Sphincterotomy                                                                                                        
   Biliary and pancreatic                                                      29 (61.7%)           46 (62.1%)          1
   Pancreatic only                                                             13 (27.6%)           8 (10.8%)           0.02
   Biliary only                                                                2 (4.2%)             12 (16.2%)          0.04
   None                                                                        3 (6.3%)             8 (10.8%)           1
  Pancreatic duct stent placement                                              43 (91.4%)           63 (85.1%)          0.24
  History of recurrent acute pancreatitis                                      24 (51%)             36 (48.6%)          0.85
  History of PEP                                                               4 (8.5%)             5 (6.7%)            0.73
  Evidence of chronic pancreatitis                                             13 (27.6%)           18 (24.3%)          0.83

**Notes:**

Some patients have more than one diagnosis

includes patients with basal sphincter of Oddi pressures ≥ 40 mmHg in either the biliary or pancreatic sphincter segment.

**Abbreviations:** IPMN, intraductal papillary mucinous neoplasm; PEP, post-endoscopic retrograde cholangiopancreatography pancreatisis; ERCP, endoscopic retrograde cholangiopancreatography.

###### 

Pancreatic fat content in head, body, and tail in patients with post-ERCP pancreatitis versus controls

  Patient groups   n    Mean    SD    *P*-values
  ---------------- ---- ------- ----- ------------
  Head fat                            
   Controls        74   5.50%   7.7   0.63
   PEP cases       47   4.90%   6.7   
  Body fat                            
   Controls        74   5.40%   7.7   0.59
   PEP cases       47   6.20%   8.4   
  Tail fat                            
   Controls        74   4.90%   6.7   0.81
   PEP cases       47   5.30%   7.6   

**Abbreviations:** PEP, post-endoscopic retrograde cholangiopancreatography pancreatisis; SD, standard deviation; ERCP, endoscopic retrograde cholangiopancreatography.

###### 

Relationship between severity of pancreatitis post-endoscopic retrograde cholangiopancreatography and pancreatic fat content

             Controls (n = 74)   Mild pancreatitis(n = 41)   Moderate to severe pancreatitis (n = 6)   *P*-values
  ---------- ------------------- --------------------------- ----------------------------------------- ------------
  Head fat   5.60%               4.90%                       5.20%                                     0.88
  Body fat   5.50%               6.50%                       4.80%                                     0.77
  Tail fat   5.00%               5.90%                       1.10%                                     0.29

###### 

Pearson correlation between mean body mass index and fat content in head, body, and tail

                            Head fat            Body fat            Tail fat
  ------------------------- ------------------- ------------------- -------------------
  **BMI (kg/m^2^)**                                                 
  Correlation coefficient                                           
   PEP cases                0.17 (*P* = 0.39)   0.31 (*P* = 0.12)   0.16 (*P* = 0.43)
   Controls                 0.13 (*P* = 0.44)   0.22 (*P* = 0.16)   0.09 (*P* = 0.60)

**Abbreviations:** BMI, body mass index; PEP, post-endoscopic retrograde cholangiopancreatography pancreatisis.
